[CAS NO. 16506-27-7] Bendamustine

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [16506-27-7]

Catelog

HY-13567

Brand

MCE

CAS

16506-27-7

DESCRIPTION [16506-27-7]

Overview

MDL	MFCD00866481
Molecular Weight	358.26
Molecular Formula	C16H21Cl2N3O2
SMILES	O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis . Bendamustine has potent alkylating, anticancer and antimetabolite properties ^[1] .

IC50 & Target

DNA Alkylator/Crosslinker ^[1]

In Vitro

Bendamustine is a DNA cross-linking agent that causes DNA breaks, with alkylating and antimetabolite properties. Bendamustine uniquely regulates apoptosis pathways and DNA repair pathways in non-Hodgkin's lymphoma cells. Bendamustine (50 μM) induces p21 (Cip1/Waf1) and NOXA genes, and increases the expression of p53 in SU-DHL-1 cells. Bendamustine (25 μM) blocks mitotic checkpoints and cuases mitotic catastrophe ^[1] .
Bendamustine reduces the viability of multiple myeloma (MM) cell lines, such as RPMI-8226 and 8226-LR5 cells, with IC ₂₅ s of 101.8 μM and 585.5 μM after 24 h incubation, and 51.7 and 374.3 μM after 48 h incubation, respectively. Bendamustine induces a specific caspase-dependent MM cell death and inhibits the spindle-assembly checkpoint ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bendamustine (25 mg/kg, i.v.) shows potent inhibition on the growth of tumor cells by 91%, 99% and 95% for DoHH-2, Granta 519 and RAMOS models, respectively. Moreover, the antitumor effect of Bendamustine is enhanced by rituximab in DoHH-2 and RAMOS models, but not in Granta 519 model ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00951457	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Mundipharma Pte Ltd.	Leukemia, Lymphocytic, Chronic, B-Cell	March 2009	Phase 1\|Phase 2
NCT01716806	Seagen Inc.\|Bristol-Myers Squibb	Hodgkin Disease\|Peripheral T Cell Lymphoma	October 31, 2012	Phase 2
NCT01109264	Jiangsu Simcere Pharmaceutical Co., Ltd.	Chronic Lymphocytic Leukemia	March 2010	Phase 2
NCT01141725	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|de Novo Myelodysplastic Syndromes\|Myelodysplastic Syndrome With Isolated Del(5q)\|Untreated Adult Acute Myeloid Leukemia	September 2010	Phase 1\|Phase 2
NCT00069758	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma	September 2003	Phase 2
NCT00920855	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Multiple Myeloma	June 2009	Phase 1\|Phase 2
NCT00880815	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	CD20 Positive\|Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Recurrent Diffuse Large B-Cell Lymphoma\|T-Cell Non-Hodgkin Lymphoma	February 17, 2009	Phase 1
NCT04023071	Fate Therapeutics	Acute Myelogenous Leukemia\|B-cell Lymphoma	October 4, 2019	Phase 1
NCT01152203	M.D. Anderson Cancer Center\|Cephalon\|National Comprehensive Cancer Network	Advanced Cancer	June 2010	Phase 1
NCT00879073	H. Lee Moffitt Cancer Center and Research Institute\|National Comprehensive Cancer Network\|Cephalon	Brain Metastases	April 2009	Phase 1
NCT04083495	UNC Lineberger Comprehensive Cancer Center	Peripheral T Cell Lymphoma	September 17, 2019	Phase 2
NCT01754857	University of Wisconsin, Madison\|Celgene Corporation\|Genentech, Inc.	Lymphoid Leukemia\|Small Lymphocytic Lymphoma\|Lymphoma, Non-Hodgkin	November 12, 2013	Phase 2
NCT00939328	Southwest Oncology Group\|National Cancer Institute (NCI)	Leukemia	September 2009	Phase 2
NCT03524235	Noah Merin\|Miltenyi Biomedicine GmbH\|Teva Branded Pharmaceutical Products R&D, Inc.\|Cedars-Sinai Medical Center	Multiple Myeloma\|CLL\|Chronic Lymphocytic Leukemia\|Lymphoma\|Hodgkin Lymphoma	July 18, 2018	Phase 1
NCT00426855	Peter Moosmann\|Kantonsspital Aarau	Lymphoma, Non-Hodgkin	January 2007	Phase 1\|Phase 2
NCT05352828	Tessa Therapeutics\|Bristol-Myers Squibb	Classical Hodgkin Lymphoma\|Hodgkin Disease Refractory\|Hodgkin Disease Recurrent	July 25, 2022	Phase 1
NCT01754402	Cristina Gasparetto\|Celgene\|Duke University	Multiple Myeloma	January 7, 2013	Phase 1\|Phase 2
NCT04083898	Washington University School of Medicine\|Sanofi	Multiple Myeloma	April 3, 2020	Phase 1\|Phase 2
NCT05139017	Merck Sharp & Dohme LLC	DLBCL\|Diffuse Large B-Cell Lymphoma	January 14, 2022	Phase 2\|Phase 3
NCT01900509	St. Jude Children´s Research Hospital\|Teva Pharmaceuticals USA	Hodgkin Lymphoma\|Non-Hodgkin Lymphoma\|Acute Leukemia	August 2013	Phase 1
NCT02168140	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Adult Lymphocyte Depletion Hodgkin Lymphoma\|Adult Lymphocyte Predominant Hodgkin Lymphoma\|Adult Mixed Cellularity Hodgkin Lymphoma\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Adult Nodular Sclerosis Hodgkin Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Hepatosplenic T-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|T-cell Adult Acute Lymphoblastic Leukemia\|T-cell Large Granular Lymphocyte Leukemia	September 2014	Phase 1
NCT01650701	The Lymphoma Academic Research Organisation\|Celgene Corporation	Follicular Lymphoma	February 2012	Phase 3
NCT01326702	National Cancer Institute (NCI)	Adult B Acute Lymphoblastic Leukemia\|Adult Nasal Type Extranodal NK+T-Cell Lymphoma\|Adult Solid Neoplasm\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-Cell Lymphoma\|Chronic Lymphocytic Leukemia\|Cutaneous B-Cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Hepatosplenic T-Cell Lymphoma\|Intraocular Lymphoma\|Lymphomatous Involvement of Non-Cutaneous Extranodal Site\|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma\|Nodal Marginal Zone Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-Cell Leukemia+Lymphoma\|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides and Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Plasma Cell Myeloma\|Small Intestinal Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenstrom Macroglobulinemia	July 2011	Phase 1\|Phase 2
NCT02594163	Seagen Inc.	Diffuse Large B-cell Lymphoma Refractory\|Follicular B-cell Non-Hodgkin´s Lymphoma	October 2015	Phase 2
NCT01657955	Shandong Lanjin Pharmaceuticals Co.,Ltd	Chronic Lymphocytic Leukemia\|Leukemia\|Neoplasms	January 2011	Phase 3
NCT05371093	Kite, A Gilead Company\|Gilead Sciences	Relapsed+Refractory Follicular Lymphoma	September 12, 2022	Phase 3
NCT01423032	WiSP Wissenschaftlicher Service Pharma GmbH\|Klinikum Leverkusen gGmbH\|ribosepharm GmbH\|Mundipharma Research GmbH & Co KG	Chronic Lymphocytic Leukemia	September 2001	Phase 2\|Phase 3
NCT02168907	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	December 2014	Phase 1
NCT01059786	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hairy Cell Leukemia	July 1, 2010	Phase 2
NCT01520922	Novartis Pharmaceuticals\|Novartis	Chronic Lymphocytic Leukemia (CLL)\|Leukaemia, Lymphocytic, Chronic	March 2012	Phase 2
NCT01701076	Cantonal Hospital of St. Gallen\|Celgene Corporation\|Mundipharma Research GmbH & Co KG\|Mundipharma Medical Company\|Amgen	Multiple Myeloma	March 2012	Phase 2
NCT00825149	Hoffmann-La Roche	Non-Hodgkin´s Lymphoma	February 2009	Phase 1
NCT01317901	Aptevo Therapeutics	B-cell Small Lymphocytic Lymphoma Recurrent	May 2011	Phase 1
NCT01570049	Shandong Lanjin Pharmaceuticals Co.,Ltd	Non-Hodgkin Lymphoma by Clinical Course	April 2010	Phase 3
NCT02381899	Czech CLL Study Group	Chronic Lymphocytic Leukemia	September 2014
NCT01294579	Novartis Pharmaceuticals\|Novartis	Lymphoma, Non-Hodgkin	May 17, 2011	Phase 2
NCT03492775	Prof. Dr. Wolfgang Hiddemann\|Hoffmann-La Roche\|Mundipharma Research GmbH & Co KG\|Ludwig-Maximilians - University of Munich	Indolent Non-hodgkin Lymphoma	December 12, 2017	Phase 2
NCT01088048	Gilead Sciences	Indolent Non-Hodgkin´s Lymphoma\|Chronic Lymphocytic Leukemia\|Mantle Cell Lymphoma	March 25, 2010	Phase 1
NCT04155840	University of Washington\|Bayer	Lymphoid Leukemia\|Non-Hodgkin´s Lymphoma\|Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	January 31, 2020	Phase 2
NCT03593018	The Lymphoma Academic Research Organisation\|Celgene	Relapsed Angioimmunoblastic T-Cell Lymphoma\|Refractory Angioimmunoblastic T-cell Lymphoma	November 9, 2018	Phase 3
NCT03269669	National Cancer Institute (NCI)	Grade 1 Follicular Lymphoma\|Grade 2 Follicular Lymphoma\|Grade 3a Follicular Lymphoma\|Recurrent Follicular Lymphoma\|Refractory Follicular Lymphoma	August 10, 2017	Phase 2
NCT01458366	Sidney Kimmel Cancer Center at Thomas Jefferson University\|GlaxoSmithKline\|Novartis\|Thomas Jefferson University	Non-Hodgkin´s Lymphoma	November 9, 2011	Phase 1\|Phase 2
NCT01724021	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma, Non-Hodgkin´s Lymphoma	December 2012	Phase 3
NCT04745832	MEI Pharma, Inc.\|Kyowa Kirin, Inc.	Follicular Lymphoma (FL)\|Non Hodgkin Lymphoma\|Marginal Zone Lymphoma	August 13, 2021	Phase 3
NCT01594229	AbbVie\|Genentech, Inc.	Non-Hodgkin´s Lymphoma	May 21, 2012	Phase 1
NCT01049945	Mayo Clinic	Refractory Multiple Myeloma	February 2010	Phase 1\|Phase 2
NCT02758925	University Hospital, Caen	Diffuse Large B Cell Lymphoma	June 2016	Phase 2
NCT03997968	Cyteir Therapeutics, Inc.	Malignancy\|Non-hodgkin Lymphoma\|Multiple Myeloma\|Breast Cancer\|Ovarian Cancer\|Soft Tissue Sarcoma\|Head and Neck Cancer\|DLBCL\|Mantle Cell Lymphoma\|Follicular Lymphoma\|Pancreatic Cancer\|CLL\|Small Cell Lung Cancer\|Squamous Cell Carcinoma of Head and Neck\|Triple Negative Breast Cancer	October 9, 2019	Phase 1\|Phase 2
NCT01415752	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Lymphoma\|Neurotoxicity\|Therapy-related Toxicity	May 22, 2012	Phase 2
NCT03755804	St. Jude Children´s Research Hospital\|Teva Pharmaceuticals USA\|Seagen Inc.	Hodgkin Lymphoma	December 12, 2018	Phase 2
NCT01490723	M.D. Anderson Cancer Center\|Spectrum Pharmaceuticals, Inc	Leukemia\|Lymphoma	January 2013	Phase 2
NCT01188681	Aptevo Therapeutics	Chronic Lymphocytic Leukemia (CLL)	September 2010	Phase 1\|Phase 2
NCT00863850	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Malignancy	May 2009	Phase 1
NCT04569838	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Indolent B-Cell Non-Hodgkin´s Lymphomas	May 2012	Phase 2
NCT02005471	Hoffmann-La Roche\|AbbVie	Chronic Lymphocytic Leukemia	March 17, 2014	Phase 3
NCT04138875	Yale University	PTLD\|Lymphoid Tumor\|Hematopoietic+Lymphoid Cancer\|Plasmacytic Hyperplasia PTLD\|Infectious Mononucleosis\|Florid Follicular Hyperplasia PTLD\|Polymorphic PTLD\|Monomorphic PTLD\|Classical Hodgkin Lymphoma Type PTLD	January 2022	Phase 2
NCT01165112	University of Washington\|National Cancer Institute (NCI)	Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma	September 2010	Phase 1\|Phase 2
NCT00947388	Case Comprehensive Cancer Center\|Cephalon	Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Small Lymphocytic Lymphoma	November 2008	Phase 1
NCT04913103	Czech Lymphoma Study Group	Lymphoma, Mantle-Cell	September 1, 2021	Phase 2
NCT04268706	Tessa Therapeutics	Hodgkin Lymphoma, Adult\|Hodgkin Disease Recurrent\|Hodgkin Disease Refractory\|Hodgkin Disease, Pediatric	February 1, 2021	Phase 2
NCT03914885	UNC Lineberger Comprehensive Cancer Center	Hodgkin Lymphoma, Adult
NCT04624906	Sunnybrook Health Sciences Centre\|AstraZeneca	Waldenstrom Macroglobulinemia	March 2, 2021	Phase 2
NCT02162888	Eagle Pharmaceuticals, Inc.	Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate	November 2013	Phase 1
NCT04217317	Wake Forest University Health Sciences\|National Cancer Institute (NCI)	Relapsed T-Cell Lymphoma\|Refractory T-Cell Lymphoma\|Non Hodgkin Lymphoma	September 16, 2020	Phase 2
NCT04897477	Chinese PLA General Hospital	Non-hodgkin Lymphoma,B Cell	April 22, 2021	Phase 1\|Phase 2
NCT02747732	Meirav Kedmi MD\|Johnson & Johnson\|Sheba Medical Center	Diffuse Large B Cell Lymphoma\|Primary Mediastinal (Thymic) Large B-cell Lymphoma\|Transformed Indolent Lymphoma\|Recurrent Disease\|Refractory Cancer	December 2016	Phase 2
NCT00758693	University of Kentucky\|Cephalon	Chronic Lymphocytic Leukemia	October 2008	Phase 2
NCT02733042	Celgene	Lymphoma\|Leukemia, Lymphocytic, Chronic, B-Cell	May 11, 2016	Phase 1\|Phase 2
NCT03315520	State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia	Relapsed+Refractory Malignant Lymphomas	January 22, 2016	Phase 2
NCT01535924	Beth Christian\|Ohio State University Comprehensive Cancer Center	Adult Lymphocyte Depletion Hodgkin Lymphoma\|Adult Lymphocyte Predominant Hodgkin Lymphoma\|Adult Mixed Cellularity Hodgkin Lymphoma\|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma\|Adult Nodular Sclerosis Hodgkin Lymphoma\|Recurrent Adult Hodgkin Lymphoma	February 9, 2012	Phase 1\|Phase 2
NCT02689141	German CLL Study Group\|Gilead Sciences\|Novartis Pharmaceuticals	Chronic Lymphocytic Leukemia	February 4, 2016	Phase 2
NCT00974233	University of Wisconsin, Madison\|Celgene Corporation	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	October 2009	Phase 2
NCT05006469	Liao Aijun\|Shengjing Hospital	Bendamustine\|Multiple Myeloma	June 1, 2021	Phase 3
NCT02853370	International Extranodal Lymphoma Study Group (IELSG)	Marginal Zone B-cell Lymphoma	July 2012	Phase 2
NCT01974440	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Lymphoma	January 31, 2014	Phase 3
NCT01664910	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hematopoietic and Lymphoid Cell Neoplasm	October 29, 2012	Phase 1\|Phase 2
NCT02420210	University of Chicago\|National Cancer Institute (NCI)	Diffuse Large B-Cell Lymphoma	November 2015	Phase 2
NCT02315157	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University	Multiple Myeloma\|Plasma Cell Leukemia		Phase 1
NCT01644253	Aptevo Therapeutics	Chronic Lymphocytic Leukemia\|Peripheral T-cell Lymphoma	September 2012	Phase 1
NCT02972840	Acerta Pharma BV\|AstraZeneca	Lymphoma, Mantle Cell	April 5, 2017	Phase 3
NCT00991211	University of Giessen	Non-Hodgkin Lymphomas\|Follicular Lymphomas\|Immunocytomas\|Lymphocytic Lymphomas\|Marginal Zone Lymphomas	January 2004	Phase 3
NCT01596621	Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin Lymphoma	August 6, 2012	Phase 3
NCT01369849	National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia	September 2011	Phase 1\|Phase 2
NCT03834688	PrECOG, LLC.\|Genentech, Inc.	Mantle Cell Lymphoma	January 13, 2020	Phase 2
NCT01871675	SCRI Development Innovations, LLC\|Infinity Pharmaceuticals, Inc.	Lymphoma\|Chronic Lymphocytic Leukemia\|Non-Hodgkin Lymphoma\|T-cell Lymphoma	May 2013	Phase 1
NCT02320383	Munich Municipal Hospital\|German CLL Study Group	Chronic Lymphocytic Leucemia	November 2014	Phase 2
NCT04607772	Karyopharm Therapeutics Inc	Relapsed or Refractory Diffuse Large B-Cell Lymphoma	November 18, 2020	Phase 1\|Phase 2
NCT02763319	MorphoSys AG\|ICON Clinical Research	Diffuse Large B-cell Lymphoma	June 2016	Phase 2\|Phase 3
NCT01523860	Fondazione Italiana Linfomi ONLUS\|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte	Follicular Lymphoma	June 2009	Phase 2
NCT02836639	Pusan National University Hospital	Lymphoma, Non-Hodgkin	February 2016	Phase 2
NCT01376401	PETHEMA Foundation\|Mundipharma Pharmaceuticals B.V.\|Janssen-Cilag Ltd.	Multiple Myeloma	July 2011	Phase 2
NCT04666038	Loxo Oncology, Inc.\|Eli Lilly and Company	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	March 9, 2021	Phase 3
NCT03778073	TG Therapeutics, Inc.	B-cell Non Hodgkin Lymphoma\|Richter´s Transformation	April 17, 2019	Phase 1
NCT01022021	University of Kansas Medical Center\|Cephalon	Lymphoma	January 2010	Early Phase 1
NCT01096992	M.D. Anderson Cancer Center	Leukemia	April 19, 2010	Phase 1\|Phase 2
NCT01234467	UNC Lineberger Comprehensive Cancer Center\|Cephalon	Diffuse Large B-Cell Lymphoma\|Lymphoma, Diffuse Large-Cell\|Diffuse Large-Cell Lymphoma\|Lymphoma	March 2011	Phase 2
NCT01649622	M.D. Anderson Cancer Center	Leukemia\|Lymphoma	December 2012	Phase 2
NCT00901927	M.D. Anderson Cancer Center\|Cephalon	Follicular Lymphoma	May 2009	Phase 2
NCT00891839	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Mantle Cell Lymphoma	June 2009	Phase 2
NCT04942730	St. Petersburg State Pavlov Medical University	Leukemia, Acute Lymphoblastic\|Myeloid Leukemia, Acute\|Biphenotypic Acute Leukemia\|Lymphoblastic Lymphoma\|Myelodysplastic Syndromes\|Myeloproliferative Neoplasm	January 21, 2021	Phase 2
NCT04943302	Tufts Medical Center\|Sanofi	Amyloidosis\|Light Chain (AL) Amyloidosis	September 2022	Phase 2
NCT01315873	NYU Langone Health\|Cephalon	Multiple Myeloma	September 2011	Phase 2
NCT00916058	Weill Medical College of Cornell University	Multiple Myeloma	April 23, 2009	Phase 1\|Phase 2
NCT01170052	Charite University, Berlin, Germany\|Wyeth is now a wholly owned subsidiary of Pfizer\|Mundipharma K.K.	Mantle Cell Lymphoma	May 2010	Phase 1\|Phase 2
NCT04127916	Samsung Medical Center	Mantle Cell Lymphoma	January 30, 2020
NCT01891227	Arbeitsgemeinschaft medikamentoese Tumortherapie	Breast Cancer	August 9, 2013	Phase 2
NCT02401503	German CLL Study Group\|Hoffmann-La Roche\|AbbVie	Chronic Lymphocytic Leucemia	May 6, 2015	Phase 2
NCT01874054	Seagen Inc.	Hodgkin Disease	June 2013	Phase 1\|Phase 2
NCT00547534	University of Rochester\|Millennium Pharmaceuticals, Inc.\|Cephalon	Non-Hodgkin´s Lymphoma	October 2007	Phase 2
NCT01168804	Austrian Forum Against Cancer	Multiple Myeloma	June 2010	Phase 2
NCT01313611	The Lymphoma Academic Research Organisation	Follicular Lymphoma	February 2011	Phase 2
NCT01221103	Southern Europe New Drug Organization\|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Lymphoma, Mantle-Cell	April 2010	Phase 1\|Phase 2
NCT00987493	Swiss Group for Clinical Cancer Research	Lymphoma	September 2009	Phase 1\|Phase 2
NCT01980888	Gilead Sciences	Chronic Lymphocytic Leukemia	February 5, 2014	Phase 3
NCT01884441	Armando Santoro, MD\|Istituto Clinico Humanitas	Hodgkin´s Lymphoma	July 2011	Phase 2
NCT02224729	Sidney Kimmel Cancer Center at Thomas Jefferson University\|Thomas Jefferson University	Stage I Multiple Myeloma\|Stage II Multiple Myeloma\|Stage III Multiple Myeloma	August 25, 2014	Phase 2
NCT01661881	Dana-Farber Cancer Institute\|Massachusetts General Hospital	Mantle Cell Lymphoma	August 16, 2012	Phase 2
NCT01776840	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Mantle Cell Lymphoma	May 16, 2013	Phase 3
NCT01657331	Columbia University	Hodgkin Lymphoma\|Anaplastic Large Cell Lymphoma	July 2012	Phase 1\|Phase 2
NCT02345863	German CLL Study Group\|Hoffmann-La Roche\|Janssen-Cilag Ltd.	Chronic Lymphocytic Leucemia	January 16, 2015	Phase 2
NCT04663347	Genmab\|AbbVie	Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma	November 16, 2020	Phase 1\|Phase 2
NCT02596971	Hoffmann-La Roche	Diffuse Large B-Cell Lymphoma, Lymphoma Follicular	December 22, 2015	Phase 1\|Phase 2
NCT05508867	Merck Sharp & Dohme LLC	Hodgkin Lymphoma	October 18, 2022	Phase 3
NCT04115631	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Liver Lymphoma\|Mantle Cell Lymphoma	October 3, 2019	Phase 2
NCT02095834	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Plasma Cell Myeloma\|Refractory Plasma Cell Myeloma	April 24, 2014	Phase 1
NCT01286272	National Cancer Institute (NCI)	Ann Arbor Stage III Grade 1 Follicular Lymphoma\|Ann Arbor Stage III Grade 2 Follicular Lymphoma\|Ann Arbor Stage III Grade 3 Follicular Lymphoma\|Ann Arbor Stage IV Grade 1 Follicular Lymphoma\|Ann Arbor Stage IV Grade 2 Follicular Lymphoma\|Ann Arbor Stage IV Grade 3 Follicular Lymphoma\|Grade 3a Follicular Lymphoma	April 8, 2011	Phase 2
NCT02623920	University of Arizona	Diffuse Large B Cell Lymphoma\|Mediastinal Large B-cell Lymphoma\|Grey Zone Lymphoma\|High Grade B Cell Lymphoma\|Follicular Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma	December 16, 2015	Phase 2
NCT02002598	Siyang Leng\|Columbia University	Multiple Myeloma	November 2013	Phase 1\|Phase 2
NCT03623373	Washington University School of Medicine\|Acerta Pharma BV	Mantle Cell Lymphoma	November 29, 2018	Phase 2
NCT01423539	Genentech, Inc.\|AbbVie (prior sponsor, Abbott)	Diffuse Large B-Cell Lymphoma	October 2011	Phase 2
NCT02424851	Oxford University Hospitals NHS Trust\|Janssen-Cilag Ltd.\|Bloodwise\|University of Warwick\|University of Birmingham	Multiple Myeloma\|Chronic Kidney Disease	November 2014	Phase 2
NCT01177683	Sherif Farag, MB, BS\|Hoosier Cancer Research Network\|Cephalon	Multiple Myeloma	July 2010	Phase 1\|Phase 2
NCT01526694	Azienda Ospedaliera di Bolzano\|Mundipharma Pte Ltd.	Multiple Myeloma	July 2012	Phase 2
NCT03787264	German CLL Study Group	Chronic Lymphoid Leukemia	January 14, 2019	Phase 2
NCT02970318	Acerta Pharma BV	Chronic Lymphocytic Leukemia	February 2, 2017	Phase 3
NCT01691807	Novartis Pharmaceuticals\|Novartis	Cancer	January 2013	Phase 1
NCT01073163	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	February 2010	Phase 3
NCT00959686	French Innovative Leukemia Organisation\|Mundipharma Pte Ltd.	T-cell Lymphoma	September 2009	Phase 2
NCT03406156	AbbVie	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	August 10, 2018	Phase 3
NCT00274989	German CLL Study Group\|University of Cologne	Chronic Lymphocytic Leukemia	November 2005	Phase 2
NCT04285567	Hoffmann-La Roche	Chronic Lymphocytic Leukemia (CLL)	May 28, 2020	Phase 3
NCT00834678	Ohio State University Comprehensive Cancer Center\|National Comprehensive Cancer Network\|Genentech, Inc.	Breast Cancer	April 2009	Phase 1\|Phase 2
NCT01832922	Dartmouth-Hitchcock Medical Center\|National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	April 2013	Phase 1
NCT01289223	Mundipharma Research Limited	Indolent B-cell NHL	February 2011	Phase 3
NCT01056510	Hoffmann-La Roche	Lymphocytic Leukemia, Chronic	March 2010	Phase 4
NCT02130869	St. Jude Children´s Research Hospital	Neuroblastoma\|Lymphoma\|High-risk Tumor	October 10, 2014	Phase 1
NCT02257567	Hoffmann-La Roche	Lymphoma	October 15, 2014	Phase 1\|Phase 2
NCT00705250	Memorial Sloan Kettering Cancer Center\|Cephalon	Hodgkin´s Disease\|Lymphoma	June 2008	Phase 2
NCT02996773	University of Arizona	Acute Lymphoblastic Leukemia\|Acute Myelogenous Leukemia\|Myelodysplastic Syndromes\|Chronic Myelogenous Leukemia\|Lymphoma,Non-Hodgkin\|Lymphoma, Hodgkin\|Lymphoma, Follicular\|Marginal Zone Lymphoma\|Large Cell Lymphoma\|Mantle-Cell Lymphoma\|Gray Zone Lymphoma\|Burkitt Lymphoma\|High Risk Undifferentiated Acute Leukemia	November 29, 2016	Phase 1\|Phase 2
NCT00385125	University of Magdeburg	Lymphoma, High-Grade	August 2004	Phase 2
NCT04762745	Sun Yat-sen University	Relapsed, Refractory, Multiple Myeloma	February 2021	Phase 1\|Phase 2
NCT01127841	Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas	Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.	July 2009	Phase 2
NCT03872180	Emory University\|Genentech, Inc.	CCND1 Positive\|Mantle Cell Lymphoma\|t(11;14) Positive	April 11, 2019	Phase 2
NCT01491841	Anne Beaven, MD\|CTI BioPharma\|Duke University	Non-Hodgkin´s Lymphoma	November 1, 2011	Phase 1
NCT01686321	University of Göttingen\|Roche Pharma AG\|Mundipharma Research GmbH & Co KG	Aggressive Lymphoma	July 4, 2012	Phase 2
NCT05551936	Vaishalee Kenkre\|Epizyme, Inc.\|University of Wisconsin, Madison\|Big Ten Cancer Research Consortium	Follicular Lymphoma	November 2022	Phase 1\|Phase 2
NCT02445131	German CLL Study Group\|Hoffmann-La Roche\|Gilead Sciences	Chronic Lymphocytic Leucemia	May 28, 2015	Phase 2
NCT02187861	Hoffmann-La Roche\|AbbVie	Follicular Lymphoma	December 1, 2014	Phase 2
NCT02799147	St. Petersburg State Pavlov Medical University	Leukemia, Acute Lymphoblastic\|Acute Myeloid Leukemia\|Mixed-Lineage Acute Leukemias	June 2016	Phase 1\|Phase 2
NCT02320487	Genentech, Inc.	Chronic Lymphocytic Leukemia	March 31, 2015	Phase 2
NCT03602157	UNC Lineberger Comprehensive Cancer Center\|University Cancer Research Fund at Lineberger Comprehensive Cancer Center\|Stand Up To Cancer	Lymphoma\|Immune System Diseases\|Immunoproliferative Disorders\|Lymphatic Diseases\|Lymphoproliferative Disorders\|Neoplasms\|Cutaneous Lymphoma\|Cutaneous Anaplastic Large Cell Lymphoma\|Mycosis Fungoides\|Sezary Syndrome\|Lymphomatoid Papulosis\|Cutaneous T Cell Lymphoma\|Gray Zone Lymphoma	December 12, 2018	Phase 1
NCT02954406	Millennium Pharmaceuticals, Inc.\|Takeda	Lymphoma, Non-Hodgkin	March 5, 2017	Phase 1
NCT00661739	German Breast Group	Metastatic Breast Cancer	July 2005	Phase 1
NCT01429025	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)\|Celgene Corporation	Refractory+Relapsed Indolent Non-Hodgkin Lymphoma	May 2012	Phase 1
NCT01352312	Sidney Kimmel Cancer Center at Thomas Jefferson University\|GlaxoSmithKline\|Novartis\|Thomas Jefferson University	Chronic Lymphocytic Leukemia\|B-Cell Non-Hodgkin´s Lymphoma	May 25, 2011	Phase 1
NCT00790855	M.D. Anderson Cancer Center\|Cephalon	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Acute Lymphoblastic Leukemia\|Chronic Myeloid Leukemia	November 2008	Phase 1\|Phase 2
NCT01754870	University of Wisconsin, Madison\|Celgene Corporation\|Genentech, Inc.	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	November 2013	Phase 2
NCT04943757	St. Petersburg State Pavlov Medical University	Myeloid Leukemia, Acute\|Chronic Myeloid Leukemia\|Myelodysplastic Syndromes\|Myeloproliferative Neoplasm	January 21, 2021	Phase 2
NCT01077518	Novartis Pharmaceuticals\|Novartis	Lymphoma, Follicular	August 26, 2010	Phase 3
NCT03343652	St. Petersburg State Pavlov Medical University	Hodgkin´s Lymphoma	May 27, 2017	Phase 1\|Phase 2
NCT01686386	Gruppo Italiano Studio Linfomi	Multiple Myeloma	February 2010	Phase 1\|Phase 2
NCT02071225	Hoffmann-La Roche	Chronic Lymphocytic Leukemia	April 9, 2014	Phase 2
NCT01569295	Gilead Sciences	Chronic Lymphocytic Leukemia	June 15, 2012	Phase 3
NCT01300247	Genentech, Inc.	Lymphocytic Leukemia, Chronic	May 2011	Phase 1
NCT01056276	SCRI Development Innovations, LLC\|Millennium Pharmaceuticals, Inc.\|Cephalon	Multiple Myeloma	May 2010	Phase 2
NCT05451771	Rajshekhar Chakraborty, MD\|Genentech, Inc.\|Columbia University	AL Amyloidosis	October 26, 2022	Phase 1\|Phase 2
NCT04587687	Joseph Tuscano\|National Cancer Institute (NCI)\|Seagen Inc.\|University of California, Davis	Recurrent Follicular Lymphoma\|Refractory Follicular Lymphoma	December 4, 2020	Phase 2
NCT04515238	German CLL Study Group	Chronic Lymphoid Leukemia	October 1, 2020	Phase 2
NCT03352765	Memorial Sloan Kettering Cancer Center	Lymphoma	November 20, 2017	Phase 1
NCT03424122	Incyte Corporation	B-cell Lymphoma	July 2, 2018	Phase 1
NCT05624554	Merck Sharp & Dohme LLC	Chronic Lymphocytic Leukemia\|Small Lymphocytic Leukemia	December 22, 2022	Phase 3
NCT03259529	St. Petersburg State Pavlov Medical University	Diffuse Large B Cell Lymphoma	March 27, 2017	Phase 1\|Phase 2
NCT01611090	Janssen Research & Development, LLC\|Pharmacyclics LLC.	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	September 19, 2012	Phase 3
NCT02728531	Washington University School of Medicine	Mantle Cell Lymphoma	April 18, 2016	Phase 1
NCT01456351	University of Giessen	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	September 2003	Phase 3
NCT00877006	Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	April 30, 2009	Phase 3
NCT02950051	German CLL Study Group\|Janssen-Cilag Ltd.\|Hoffmann-La Roche\|AbbVie\|Stichting Hemato-Oncologie voor Volwassenen Nederland\|Nordic CLL Study Group (NCLLSG)\|Swiss Group for Clinical Cancer Research\|Cancer Trials Ireland\|Israeli CLL Study Group	Chronic Lymphocytic Leukemia	December 13, 2016	Phase 3
NCT02433795	Seoul National University Hospital\|Gyeongsang National University Hospital\|Korea Cancer Center Hospital\|Seoul National University Boramae Hospital\|Hallym University Medical Center\|Inje University\|Gangnam Severance Hospital\|Chonbuk National University Hospital\|Chungnam National University\|The Catholic University of Korea\|Wonju Severance Christian Hospital\|Gachon University Gil Medical Center\|Seoul National University Bundang Hospital	Marginal Zone B-cell Lymphoma	May 2015	Phase 2
NCT01234766	Dartmouth-Hitchcock Medical Center\|Cephalon\|Spectrum Pharmaceuticals, Inc	Lymphoma, Follicular	October 2010	Phase 2
NCT02499627	Fondazione Italiana Linfomi ONLUS	Lymphatic Diseases	December 23, 2015	Phase 2
NCT02110394	Astellas Pharma Europe B.V.\|Astellas Pharma Inc	Chronic Lymphocytic Leukemia	June 2012
NCT01500083	Lundbeck Canada Inc.	Indolent Non-Hodgkin´s Lymphoma\|Chronic Lymphocytic Leukemia	March 2012	Phase 3
NCT00831597	Pharmatech\|Cephalon	Diffuse Large B-Cell Lymphoma	November 2008	Phase 2
NCT01332968	Hoffmann-La Roche\|German Low Grade Lymphoma Study Group\|Institute of Cancer Research, United Kingdom	Non-Hodgkin´s Lymphoma	July 6, 2011	Phase 3
NCT01125787	Nevada Cancer Institute\|GlaxoSmithKline\|Cephalon	Chronic Lymphocytic Leukemia (CLL)	May 2010	Phase 2
NCT01059630	Genentech, Inc.\|Roche Pharma AG	Non-Hodgkin´s Lymphoma	April 30, 2010	Phase 3
NCT00139841	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma	October 2005	Phase 3
NCT02491398	Gruppo Italiano Malattie EMatologiche dell´Adulto	Chronic Lymphocytic Leukemia	February 2016
NCT00769522	German CLL Study Group\|Roche Pharma AG\|Mundipharma Pte Ltd.	Chronic Lymphocytic Leukemia	October 2, 2008	Phase 3
NCT01484626	Loyola University\|Celgene	Multiple Myeloma	May 5, 2011	Phase 1\|Phase 2
NCT04510636	University Health Network, Toronto	Classical Hodgkin Lymphoma\|Relapsed Cancer\|Refractory Cancer	December 20, 2021	Phase 2
NCT04236141	Hoffmann-La Roche	Diffuse, Large B-Cell, Lymphoma	July 10, 2020	Phase 3
NCT04882163	Celgene	Lymphoma, B-Cell	October 10, 2021	Phase 1\|Phase 2
NCT01244451	Gruppo Italiano Malattie EMatologiche dell´Adulto	Patients With CLL Relapsing After an Initial Response (CR, PR ? 6 Months) Following no More Than Two Prior Treatment Lines; or\|Patients With CLL Refractory (SD, PD or CR+PR < 6 Months) Following no More Than Two Prior Treatment Lines	December 2010	Phase 2
NCT01671904	Genentech, Inc.\|AbbVie (prior sponsor, Abbott)	Chronic Lymphocytic Leukemia	January 13, 2014	Phase 1
NCT01929265	Fondazione Italiana Linfomi ONLUS	Indolent Non-follicular\|Non-Hodgkin´s Lymphoma	January 2011	Phase 2
NCT01029730	SCRI Development Innovations, LLC\|Millennium Pharmaceuticals, Inc.\|Cephalon	Lymphoma	March 2010	Phase 2
NCT01224769	Gruppo Italiano Studio Linfomi	Relapsed or Refractory Chronic Lymphoproliferative Disorders	September 2005
NCT02134262	Jichi Medical University\|Takara Bio Inc.	Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	May 2014	Phase 1\|Phase 2
NCT03739619	Emory University\|Bristol-Myers Squibb	Recurrent Hodgkin Lymphoma\|Refractory Hodgkin Lymphoma\|Classical Hodgkin Lymphoma\|Hodgkin Lymphoma	November 26, 2018	Phase 1\|Phase 2
NCT02793583	TG Therapeutics, Inc.	Diffuse Large B-Cell Lymphoma\|Follicular Lymphoma\|Marginal Zone Lymphoma\|Mantle Cell Lymphoma\|Small Lymphocytic Lymphoma	May 25, 2016	Phase 2\|Phase 3
NCT01238146	National Cancer Institute (NCI)	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	October 2010	Phase 1\|Phase 2
NCT03856216	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|B Acute Lymphoblastic Leukemia\|Lymphocytic Neoplasm\|Lymphoma	October 28, 2019	Phase 2
NCT00636792	Millennium Pharmaceuticals, Inc.	Follicular Lymphoma	February 2008	Phase 2
NCT01010568	Georgetown University\|GlaxoSmithKline\|Cephalon	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	April 2010	Phase 2
NCT03336333	BeiGene	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	November 2, 2017	Phase 3
NCT00864942	Georgetown University\|Celgene Corporation\|Cephalon	Chronic Lymphocytic Leukemia\|Non-Hodgkin´s Lymphoma	February 2009	Phase 1
NCT01479842	Kami Maddocks, MD\|Pharmacyclics LLC.\|Ohio State University Comprehensive Cancer Center	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenstrom Macroglobulinemia	December 7, 2011	Phase 1
NCT02153580	City of Hope Medical Center\|National Cancer Institute (NCI)	B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma\|B-Cell Prolymphocytic Leukemia\|High Grade B-Cell Lymphoma, Not Otherwise Specified\|Post-Transplant Lymphoproliferative Disorder\|Recurrent Adult Burkitt Lymphoma\|Recurrent Chronic Lymphocytic Leukemia\|Recurrent Diffuse Large B-Cell Lymphoma\|Recurrent Follicular Lymphoma\|Recurrent Hairy Cell Leukemia\|Recurrent Lymphoplasmacytic Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Small Lymphocytic Lymphoma	September 24, 2014	Phase 1
NCT01905943	Hoffmann-La Roche	Chronic Lymphocytic Leukemia	November 4, 2013	Phase 3
NCT01889069	Hoffmann-La Roche	Lymphoma	July 31, 2013	Phase 3
NCT01015248	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	MALT LYMPHOMA	May 2009	Phase 2
NCT01732926	Gilead Sciences	Indolent Non-Hodgkin´s Lymphomas	January 2, 2013	Phase 3
NCT00612183	SymBio Pharmaceuticals	Non-Hodgkin´s Lymphoma\|Mantle Cell Lymphoma	December 2007	Phase 2
NCT02423837	National Research Center for Hematology, Russia	Follicular Lymphoma	December 2013	Phase 3
NCT00872976	Bristol-Myers Squibb	Chronic Lymphocytic Leukemia	May 2009	Phase 1
NCT01886872	National Cancer Institute (NCI)	Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	December 9, 2013	Phase 3
NCT02240719	University of California, Davis\|Novartis	Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Multiple Myeloma	October 2014	Phase 1
NCT00389051	SymBio Pharmaceuticals	Non-Hodgkin´s Lymphoma	October 31, 2006	Phase 1
NCT01412879	Southwest Oncology Group\|National Cancer Institute (NCI)	Lymphoma	November 2011	Phase 2
NCT01412307	Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale\|GiovanniPascale	Recurrent Adult Hodgkin Lymphoma	July 2011	Phase 1\|Phase 2
NCT00984542	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Lung Cancer	September 2009	Phase 2
NCT02006485	TG Therapeutics, Inc.	Chronic Lymphocytic Leukemia\|Non-Hodgkin´s Lymphoma	December 13, 2013	Phase 1
NCT00274963	German CLL Study Group	Chronic Lymphocytic Leukemia	October 2004	Phase 2
NCT02927769	Bristol-Myers Squibb\|Seagen Inc.	Hodgkin Disease	March 28, 2017	Phase 2
NCT03609593	Nicole Lamanna\|Columbia University	Chronic Lymphocytic Leukemia	November 12, 2018	Phase 2
NCT01131247	Nevada Cancer Institute\|Cephalon\|GlaxoSmithKline	Chronic Lymphocytic Leukemia (CLL)		Phase 2
NCT01108341	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma (NHL)	May 2010	Phase 2
NCT05023980	Loxo Oncology, Inc.\|Eli Lilly and Company	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma	September 23, 2021	Phase 3
NCT03311126	University of Wisconsin, Madison\|Genentech, Inc.	Mantle Cell Lymphoma\|Non-hodgkin Lymphoma\|Non Hodgkin Lymphoma	October 19, 2017	Phase 2
NCT00867503	University of Arizona\|Cephalon	Ovarian Cancer	February 2009	Phase 2
NCT02194374	M.D. Anderson Cancer Center\|CLL Global Research Foundation Alliance	Leukemia	January 2015	Phase 1
NCT02626455	Bayer	Lymphoma, Non-Hodgkin	January 6, 2016	Phase 3
NCT03187223	University Hospital Inselspital, Berne\|Mundipharma Medical Company	Multiple Myeloma	July 20, 2017	Phase 2
NCT01626352	SCRI Development Innovations, LLC\|Novartis\|GlaxoSmithKline\|Cephalon	Diffuse Large B-Cell Lymphoma	October 2012	Phase 2
NCT01678430	University of Liverpool\|GlaxoSmithKline\|Napp Pharmaceuticals Limited\|Chugai Pharma USA	Chronic Lymphocytic Leukaemia	December 2011	Phase 3
NCT00837928	John Grecula\|National Comprehensive Cancer Network\|Ohio State University Comprehensive Cancer Center	Metastatic Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	February 19, 2009	Phase 1
NCT02059239	Weill Medical College of Cornell University	Hodgkin´s Lymphoma\|Non-Hodgkin´s Lymphoma	June 4, 2014	Phase 1\|Phase 2
NCT01042704	Robert Redner, MD\|Cephalon\|University of Pittsburgh	Myeloma	February 2008	Phase 1
NCT00899431	M.D. Anderson Cancer Center\|Celgene Corporation	Chronic Lymphocytic Leukemia	May 6, 2009	Phase 2
NCT01466153	MedImmune LLC	Chronic Lymphocytic Leukemia (CLL)	February 7, 2012	Phase 2
NCT04849715	Incyte Corporation	Mantle Cell Lymphoma	March 11, 2022	Phase 3
NCT03615664	Polish Lymphoma Research Group	Hodgkin´s Lymphoma	November 6, 2017	Phase 2
NCT00076349	Cephalon\|Teva Branded Pharmaceutical Products R&D, Inc.	Non-Hodgkin´s Lymphoma	April 2004	Phase 2
NCT01088984	Teva Branded Pharmaceutical Products R&D, Inc.	Leukemia	August 2010	Phase 1\|Phase 2
NCT00823797	University of Washington\|National Cancer Institute (NCI)\|National Comprehensive Cancer Network	Adult Anaplastic Astrocytoma\|Adult Anaplastic Oligodendroglioma\|Adult Giant Cell Glioblastoma\|Adult Glioblastoma\|Adult Gliosarcoma\|Recurrent Adult Brain Neoplasm	October 2008	Phase 2
NCT02576275	SecuraBio	Indolent Non-Hodgkin´s Lymphoma\|Follicular Lymphoma\|Small Lymphocytic Lymphoma\|Marginal Zone Lymphoma	December 2015	Phase 3
NCT01222260	Columbia University\|Cephalon	AL Amyloidosis	January 2013	Phase 2
NCT02187133	University of California, San Francisco\|National Comprehensive Cancer Network	Lymphoma, Non-Hodgkin\|Lymphoma	May 5, 2015	Phase 1
NCT04002297	BeiGene	Mantle Cell Lymphoma; Non-Hodgkin Lymphoma	August 21, 2019	Phase 3
NCT00740415	French Innovative Leukemia Organisation\|Janssen, LP\|Mundipharma Pte Ltd.	Lymphoma	June 2007	Phase 2
NCT02414568	The Lymphoma Academic Research Organisation	Classical Hodgkin Lymphoma	July 17, 2015	Phase 2
NCT02477215	Parameswaran Hari\|Medical College of Wisconsin	Multiple Myeloma	October 9, 2015	Phase 1\|Phase 2
NCT04022239	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hematopoietic and Lymphoid System Neoplasm	March 13, 2020	Phase 1\|Phase 2
NCT04223765	UNC Lineberger Comprehensive Cancer Center	Mantle Cell Lymphoma\|Follicular Lymphoma\|Splenic Marginal Zone Lymphoma\|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue\|Nodal Marginal Zone Lymphoma\|Indolent Non-hodgkin Lymphoma	November 12, 2020	Phase 1
NCT02951156	Pfizer\|EMD Serono	Diffuse Large B-Cell Lymphoma	December 16, 2016	Phase 3
NCT02257242	Adam Olszewski\|Spectrum Pharmaceuticals, Inc\|Rhode Island Hospital\|The Miriam Hospital\|Brown University	Lymphoma, Non-Hodgkin\|Lymphoma, Follicular\|Lymphoma, Mantle-Cell\|Lymphoma, Small-Cell\|Waldenstrom Macroglobulinemia\|Lymphoma, B-Cell, Marginal Zone	May 10, 2017	Phase 1
NCT03696784	UNC Lineberger Comprehensive Cancer Center\|Bellicum Pharmaceuticals\|The V Foundation	Lymphoma\|Lymphoma, B-Cell\|Immune System Diseases\|Immunoproliferative Disorders\|Lymphatic Diseases	March 12, 2019	Phase 1
NCT01400685	Massachusetts General Hospital\|Dana-Farber Cancer Institute	Chronic Lymphocytic Leukemia\|Small Lymphocytic Lymphoma\|B Chronic Lymphocytic Leukemia	December 2012	Phase 1
NCT03817853	Hoffmann-La Roche	Advanced Follicular Lymphoma	February 26, 2019	Phase 4
NCT01110135	University of Washington\|National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Multiple Myeloma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	August 2010	Phase 2
NCT01437709	Memorial Sloan Kettering Cancer Center\|GlaxoSmithKline	Mantle Cell Lymphoma	September 2011	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 279.13 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7913 mL	13.9563 mL	27.9127 mL
5 mM	0.5583 mL	2.7913 mL	5.5825 mL
10 mM	0.2791 mL	1.3956 mL	2.7913 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.98 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1H-Benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1-methyl-

2-Benzimidazolebutyric acid, 5-[bis(2-chloroethyl)amino]-1-methyl-

5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid

ω-[1-Methyl-5-[bis(β-chloroethyl)amino]-2-benzimidazolyl]butyric acid

Bendamustine

4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid